Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2018 Filed Jun 26, 2018 00:28 UTC |
BERTHELSEN SPENCER RDirector
|
Exercise / conversionDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0000874015-18-000073 · edgar.xml · derivative · entry 6 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 00:28 UTC |
BERTHELSEN SPENCER RDirector
|
SaleCommon Stock | 9,300 | $42.47 | $394,971.00 |
DisclosureSEC source: 0000874015-18-000073 · edgar.xml · nonDerivative · entry 4 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,427 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 04/13/2018. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 04/13/2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.21 to $42.815, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 00:28 UTC |
BERTHELSEN SPENCER RDirector
|
Exercise / conversionCommon Stock | 9,300 | $13.88 | $129,084.00 |
DisclosureSEC source: 0000874015-18-000073 · edgar.xml · nonDerivative · entry 3 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 04/13/2018. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 04/13/2018. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 00:28 UTC |
BERTHELSEN SPENCER RDirector
|
SaleCommon Stock | 5,700 | $42.03 | $239,571.00 |
DisclosureSEC source: 0000874015-18-000073 · edgar.xml · nonDerivative · entry 2 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,427 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 04/13/2018. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 04/13/2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.76 to $42.20, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 00:28 UTC |
BERTHELSEN SPENCER RDirector
|
Exercise / conversionCommon Stock | 5,700 | $13.88 | $79,116.00 |
DisclosureSEC source: 0000874015-18-000073 · edgar.xml · nonDerivative · entry 1 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 04/13/2018. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 04/13/2018. Read SEC document |
| June 18, 2018 Filed Jun 18, 2018 22:33 UTC |
McDevitt DamienChief Business Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 63,750 | $0.00 Strike: $43.60 | $0.00 |
DisclosureSEC source: 0000874015-18-000071 · edgar.xml · derivative · entry 1 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 63,750 shares Expires 2025-06-17 F1 · derivative.exercise_date: Grant of 6/18/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 6/18/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 6/18/2018. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 00:02 UTC |
MUTO FREDERICK TDirector
|
Exercise / conversionNon-Employee Director Stock Option · Derivative | 15,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0000874015-18-000067 · edgar.xml · derivative · entry 4 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 00:02 UTC |
MUTO FREDERICK TDirector
|
SaleCommon Stock | 15,000 | $46.45 | $696,750.00 |
DisclosureSEC source: 0000874015-18-000067 · edgar.xml · nonDerivative · entry 2 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,127 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $46.60, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 00:02 UTC |
MUTO FREDERICK TDirector
|
Exercise / conversionCommon Stock | 15,000 | $13.88 | $208,200.00 |
DisclosureSEC source: 0000874015-18-000067 · edgar.xml · nonDerivative · entry 1 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:06 UTC |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000064 · edgar.xml · derivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13 Underlying: Common Stock · 12,500 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:06 UTC |
BENNETT C FRANKSVP, Antisense Research
|
SaleCommon Stock | 12,500 | $45.00 | $562,500.00 |
DisclosureSEC source: 0000874015-18-000064 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,114 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:06 UTC |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionCommon Stock | 12,500 | $7.25 | $90,625.00 |
DisclosureSEC source: 0000874015-18-000064 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:00 UTC |
WENDER JOSEPH HDirector
|
Exercise / conversionDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0000874015-18-000062 · edgar.xml · derivative · entry 8 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:00 UTC |
WENDER JOSEPH HDirector
|
SaleCommon Stock | 8,590 | $45.03 | $386,807.70 |
DisclosureSEC source: 0000874015-18-000062 · edgar.xml · nonDerivative · entry 6 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,249 F1 · kind: Acquired as a result of exercising a stock option. F1 · shares: Acquired as a result of exercising a stock option. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $45.40, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:00 UTC |
WENDER JOSEPH HDirector
|
Exercise / conversionCommon Stock | 8,590 | $13.88 | $119,229.20 |
DisclosureSEC source: 0000874015-18-000062 · edgar.xml · nonDerivative · entry 5 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option. F1 · shares: Acquired as a result of exercising a stock option. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:00 UTC |
WENDER JOSEPH HDirector
|
SaleCommon Stock | 6,010 | $45.79 | $275,197.90 |
DisclosureSEC source: 0000874015-18-000062 · edgar.xml · nonDerivative · entry 4 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,249 F1 · kind: Acquired as a result of exercising a stock option. F1 · shares: Acquired as a result of exercising a stock option. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.42 to $45.98, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:00 UTC |
WENDER JOSEPH HDirector
|
Exercise / conversionCommon Stock | 6,010 | $13.88 | $83,418.80 |
DisclosureSEC source: 0000874015-18-000062 · edgar.xml · nonDerivative · entry 3 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option. F1 · shares: Acquired as a result of exercising a stock option. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:00 UTC |
WENDER JOSEPH HDirector
|
SaleCommon Stock | 400 | $44.02 | $17,608.00 |
DisclosureSEC source: 0000874015-18-000062 · edgar.xml · nonDerivative · entry 2 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,249 F1 · kind: Acquired as a result of exercising a stock option. F1 · shares: Acquired as a result of exercising a stock option. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.40 to $44.26, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| May 11, 2018 Filed May 12, 2018 01:00 UTC |
WENDER JOSEPH HDirector
|
Exercise / conversionCommon Stock | 400 | $13.88 | $5,552.00 |
DisclosureSEC source: 0000874015-18-000062 · edgar.xml · nonDerivative · entry 1 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option. F1 · shares: Acquired as a result of exercising a stock option. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · derivative · entry 11 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,904 Underlying: Common Stock · 4,000 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,962 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · derivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,680 Underlying: Common Stock · 9,962 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
SaleCommon Stock | 2,000 | $44.50 | $89,000.00 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · nonDerivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,128 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 2,000 | $10.82 | $21,640.00 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · nonDerivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
SaleCommon Stock | 2,000 | $44.30 | $88,600.00 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,128 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 2,000 | $10.82 | $21,640.00 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
SaleCommon Stock | 4,981 | $44.50 | $221,654.50 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,733 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 4,981 | $14.69 | $73,170.89 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
SaleCommon Stock | 4,981 | $44.30 | $220,658.30 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,733 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 21:22 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 4,981 | $14.69 | $73,170.89 |
DisclosureSEC source: 0000874015-18-000057 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 19:51 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0000874015-18-000055 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 19:51 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 2,000 | $46.15 | $92,300.00 |
DisclosureSEC source: 0000874015-18-000055 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 19:51 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 2,000 | $24.42 | $48,840.00 |
DisclosureSEC source: 0000874015-18-000055 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:19 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0000874015-18-000053 · edgar.xml · derivative · entry 8 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:19 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 200 | $52.11 | $10,422.00 |
DisclosureSEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.03 to $52.18, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:19 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 200 | $24.42 | $4,884.00 |
DisclosureSEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:19 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 900 | $51.59 | $46,431.00 |
DisclosureSEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.85, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:19 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 900 | $24.42 | $21,978.00 |
DisclosureSEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:19 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 900 | $50.45 | $45,405.00 |
DisclosureSEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.97 to $50.95, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:19 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 900 | $24.42 | $21,978.00 |
DisclosureSEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 01:14 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-18-000051 · edgar.xml · derivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Common Stock · 1,000 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 01:14 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
SaleCommon Stock | 1,000 | $55.00 | $55,000.00 |
DisclosureSEC source: 0000874015-18-000051 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,452 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 01:14 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionCommon Stock | 1,000 | $10.82 | $10,820.00 |
DisclosureSEC source: 0000874015-18-000051 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:52 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $35.53 | $0.00 |
DisclosureSEC source: 0000874015-18-000049 · edgar.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:52 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 2,100 | $52.29 | $109,809.00 |
DisclosureSEC source: 0000874015-18-000049 · edgar.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.88 to $52.51, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:52 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 2,100 | $35.53 | $74,613.00 |
DisclosureSEC source: 0000874015-18-000049 · edgar.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:52 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 900 | $51.02 | $45,918.00 |
DisclosureSEC source: 0000874015-18-000049 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.48 to $51.39, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:52 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 900 | $35.53 | $31,977.00 |
DisclosureSEC source: 0000874015-18-000049 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 23:00 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $35.53 | $0.00 |
DisclosureSEC source: 0000874015-18-000041 · edgar.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 23:00 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 1,600 | $49.20 | $78,720.00 |
DisclosureSEC source: 0000874015-18-000041 · edgar.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.03 to $49.37, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 23:00 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 1,600 | $35.53 | $56,848.00 |
DisclosureSEC source: 0000874015-18-000041 · edgar.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.